Peleg et al. 1 constructed a novel model to predict the risk of histological progression, including into low-grade dysplasia (LGD), in patients with Barrett's esophagus (BE) without dysplasia. They built a model to predict the risk of histological progression in patients with BE by incorporating neutrophil-to-lymphocyte ratio (NLR), BE length, smoking history, age at BE diagnosis, and chronic kidney disease as parameters. In their study, the efficacy of the model was validated using an internal validation cohort. The results showed an area under curve (AUC) of 0.88 for the predictive ability of BE patients to develop dysplasia at 3 years. The most significant difference from a previous